Compare NEWT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEWT | FULC |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | 572 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.6M | 467.8M |
| IPO Year | N/A | 2019 |
| Metric | NEWT | FULC |
|---|---|---|
| Price | $14.80 | $3.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $15.33 | ★ $16.38 |
| AVG Volume (30 Days) | 292.6K | ★ 3.3M |
| Earning Date | 04-30-2026 | 04-27-2026 |
| Dividend Yield | ★ 6.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.45 | N/A |
| P/E Ratio | $5.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $2.83 |
| 52 Week High | $15.34 | $15.74 |
| Indicator | NEWT | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 59.33 | 34.50 |
| Support Level | $12.56 | $2.83 |
| Resistance Level | $15.13 | $4.02 |
| Average True Range (ATR) | 0.54 | 0.23 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 70.06 | 13.11 |
NewtekOne Inc provides business and financial solutions under the Newtek and NewtekOne brands to the independent business owner (SMB) market. Its services are offered online and in some cases delivered by staff via video and voice calls. The company offers lending products, FDIC insured deposit products and services, payments processing, payroll services and insurance brokerage services. Loan products include SBA 7(a), ALP, SBA 504, and traditional C&I and CRE bank loans, while deposit products include consumer high yield savings accounts, high yield certificates of deposit, zero-fee business checking and business money market accounts. The company operates through four reportable segments Banking, Alternative Lending, NSBF and Payments.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.